DEVELOPMENT OF A DRUG CANDIDATE AGAINST CHIKUNGUNYA VIRUS

抗基孔肯雅病毒候选药物的开发

• 批准号: 10912975
• 负责人: DANIEL STREBLOW
• 金额: $ 469.64万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-11-01 至 2024-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10912975
• 关键词: Advanced Development; Chemistry; Chikungunya virus; Clinical; Development; Pathway interactions; Virus; drug candidate; efficacy evaluation; manufacture; pandemic potential; pre-clinical; product development; research and development; safety assessment; therapeutic candidate; therapeutic development

To support the advanced development of a promising candidate therapeutic for viruses with pandemic potential. The research and development activities to be supported will allow the candidate therapeutic product to progress through the product development pathway, and include preclinical and IND enabling development activities, chemistry optimization/development, GMP manufacturing, and clinical safety and efficacy assessment.

支持对具有大流行潜力的病毒进行有前途的候选治疗的先进开发。支持的研发活动将允许候选治疗产品通过产品开发途径取得进展，包括临床前和IND开发活动，化学优化/开发，GMP制造以及临床安全性和有效性评估。